GLP-1 Drugs Linked to Lower Death Risk in Older Adults With Fatty Liver
Graded Moderate — large retrospective cohort with propensity matching of about 88,000 older adults over up to 10 years, though treatment was not randomly assigned.
- Design
- —
- Participants
- 87,860
- Duration
- —
- Funding
- —
This study suggests GLP-1 drugs may be worth discussing with a doctor for fatty liver disease.
Older adults with fatty liver disease who started a GLP-1 drug had about half the death rate of those who did not. Researchers matched around 44,000 people over 65 on each side using US medical records, tracking them up to 10 years. Liver complications and hospital stays were also lower, though heart events were not. This was not a randomized trial, so other differences between the groups could explain part of the gap, and some side effects like eye problems were more common.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
Related Studies
All researchYoung Blood Restarts Liver Repair in Old Mice, Thanks to B Cells
Old mice regrew their livers much faster after surgery when they shared blood with young mice.
Ozempic-Style Drugs May Slow Biological Aging, Not Just Shrink Waistlines
GLP-1 drugs like semaglutide cut deaths and heart problems by more than their weight and blood sugar effects alone would explain.
Why Muscle Quality Matters So Much on GLP-1 Weight Loss Drugs
Drugs like Ozempic drop weight fast, but some of that loss is muscle, not just fat.